Cogstate

We are thrilled to welcome Luka Lucić, PhD, as Senior Director, Clinical Science, Psychiatry. Dr. Lucić brings more than a decade of experience overseeing clinical outcome assessments for global biopharmaceutical programs across psychiatry, neurodevelopment, and rare disease indications. In his new role, Dr. Lucić will lead endpoint data quality for global clinical trials in psychiatry and related CNS therapeutic areas.    “We are delighted to have Luka officially join our team,” said Pam Ventola, PhD, Chief Science Officer at Cogstate. “Having collaborated with him for many years, we’ve seen firsthand how his deep knowledge of psychiatric scales leads to thoughtful endpoint selection and how his innovative training and monitoring approaches reduce both error and rater burden. His expertise will be an asset to our biopharmaceutical customers pursuing mood disorder research.” Read more: https://lnkd.in/d2Myzxje

Scenes from #AAIC25 - our team (typically spread across three continents) had the rare opportunity to spend time together in Toronto last month! As we reflect on an invigorating week of scientific discovery, research breakthroughs, and progress in the fight against Alzheimer’s disease, we are reminded of the power of collaboration and the shared commitment driving us closer to a future without AD.

People with central disorders of hypersomnolence often struggle with sustained attention—commonly measured by the Psychomotor Vigilance Test (PVT). To support future studies using the PVT as an outcome, this meta-analysis of 77 trials was presented at SLEEP 2025 (Harel, 2025), confirming the PVT’s sensitivity to cognitive impairment and change, and offering a strong foundation for its use in evaluating new treatments for sleep-wake disorders. View the poster 👉 https://buff.ly/17ANSjG

Investor Webinar | Unlocking Alzheimer’s Breakthroughs: Enabling better data-driven decisions to advance drug approvals As part of our investor webinar series, join us for an insightful conversation on the latest advancements in Alzheimer’s research and drug development. Tuesday 5 August at 9am AEST | Monday 4 August at 7pm US EST Featuring: ·      Akash Tewari, Equity Analyst, Jefferies ·      Brad O’Connor, CEO, Cogstate ·      Kaycee Sink, Chief Medical Officer, Cogstate ·      Rachel Colite, EVP Clinical Trials, Cogstate The panel will unpack key insights from AAIC 2025 and discuss: ·      Disease progression and treatment strategies ·      The evolving role of pharma in Alzheimer’s care ·      How Cogstate is supporting pre-symptomatic trials through better data Register now: https://lnkd.in/gDJwyvUu

It's showtime. #AAIC25 is in full swing in Toronto! Chat with the Cogstate team at booth 1610. #AlzheimersDisease #Alzheimers

Studies in preclinical and emergent Alzheimer’s disease indicate that learning deficits emerge well in advance of any impairment in episodic memory (Lim, 2020). Consequently, identification of these learning deficits in otherwise cognitively unimpaired older adults could provide a critical tool for the identification of very early AD and for assessing the effects of AD drugs at this early stage of the disease. In this context, Cogstate is delighted to announce the addition of the Objective Retention-based Cognitive Assessment (ORCA) suite of learning tests to our platform, allowing learning to be assessed and analyzed with rigor, precision, and accuracy. Visit our team at booth #1610 during #AAIC25 Toronto to experience the demo. Learn more about how Cogstate’s digital endpoint solutions enable clearer signal detection – book a meeting with our team during AAIC: https://buff.ly/5ptij3f

98% of Narcolepsy Type 1 (NT1) patients report experiencing cognitive difficulties. 79% report these difficulties as severe or moderate. 73% report experiencing these difficulties on a daily basis. And 64% report incomplete resolution of cognitive difficulties following NT1 drug treatment. These new findings from a poster presented at SLEEP 2025 underscore the importance of incorporating cognitive symptoms into both the clinical understanding of NT1 and the development of targeted treatments (Harel, 2025). The team at Cogstate is honored to be involved in the ongoing research acknowledging, and seeking to address, this unmet need for patients. View the poster 👉 https://buff.ly/3LX8neY

The Cogstate team will be at #AAIC25 to talk real-world innovation in Alzheimer’s research—from advanced analytics and data monitoring innovations to digital tools that are reshaping recruitment and screening. Catch Brad O'Connor, Kaycee Sink, MD, MAS, Paul Maruff, Svenja Wacker, PhD, Rachel Colite and others from our leadership team as we connect with industry partners driving the future of AD discovery. Schedule a meeting 👉 https://lnkd.in/eTSVD-Zi

We wish to congratulate the Takeda oveporexton team on positive results from their pivotal phase III program in narcolepsy type 1. We are so pleased these data indicate that treatment with oveporexton in adults with NT1 resulted in substantial benefit across multiple symptoms of the disorder, including the ability to maintain attention. This milestone underscores the potential of oveporexton to improve the lives of people with NT1.

25 Days to #AAIC25! Cogstate is back at the world’s leading Alzheimer’s conference and proud to present new science that supports better decision-making in Alzheimer’s drug development: 📋 The correlation of Cogstate’s International Shopping List Test (ISLT) sensitivity and baseline characteristics in prodromal AD 🧠Measuring the meaningfulness of thinking in preclinical AD patients 📈 The correlations of amyloid accumulation, brain atrophy, and cognitive decline in emergent AD See the full list of Cogstate’s AAIC scientific presentations 👉 : https://lnkd.in/eTSVD-Zi